Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Average Target Price from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $6.25.

A number of research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday. The Goldman Sachs Group reduced their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Finally, Needham & Company LLC reduced their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Meridian Wealth Management LLC bought a new position in shares of Esperion Therapeutics in the 1st quarter worth about $29,000. Cibc World Markets Corp bought a new position in shares of Esperion Therapeutics in the 4th quarter worth about $39,000. Synergy Asset Management LLC lifted its position in shares of Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 30,138 shares during the last quarter. Private Advisor Group LLC lifted its position in shares of Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 10,000 shares during the last quarter. Finally, Crestline Management LP bought a new position in shares of Esperion Therapeutics in the 4th quarter worth about $63,000. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Trading Down 6.8%

ESPR opened at $1.09 on Wednesday. The company has a fifty day simple moving average of $0.96 and a 200 day simple moving average of $1.63. The firm has a market cap of $216.04 million, a price-to-earnings ratio of -1.36 and a beta of 0.67. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million. On average, analysts forecast that Esperion Therapeutics will post -0.29 earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.